Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
Tamura K, Okamoto I, Kashii T, Negoro S, Hirashima T, Kudoh S, Ichinose Y, Ebi N, Shibata K, Nishimura T, Katakami N, Sawa T, Shimizu E, Fukuoka J, Satoh T, Fukuoka M; West Japan Thoracic Oncology Group. Tamura K, et al. Among authors: negoro s. Br J Cancer. 2008 Mar 11;98(5):907-14. doi: 10.1038/sj.bjc.6604249. Epub 2008 Feb 19. Br J Cancer. 2008. PMID: 18283321 Free PMC article. Clinical Trial.
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).
Sekine I, Nishiwaki Y, Noda K, Kudoh S, Fukuoka M, Mori K, Negoro S, Yokoyama A, Matsui K, Ohsaki Y, Nakano T, Saijo N; Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group. Sekine I, et al. Among authors: negoro s. Ann Oncol. 2003 May;14(5):709-14. doi: 10.1093/annonc/mdg213. Ann Oncol. 2003. PMID: 12702524 Free article. Clinical Trial.
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M. Ohe Y, et al. Among authors: negoro s. Ann Oncol. 2007 Feb;18(2):317-23. doi: 10.1093/annonc/mdl377. Epub 2006 Nov 1. Ann Oncol. 2007. PMID: 17079694 Free article. Clinical Trial.
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.
Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Itoh Y, Tamura T, Saijo N, Fukuoka M. Sekine I, et al. Among authors: negoro s. Ann Oncol. 2009 Sep;20(9):1483-1488. doi: 10.1093/annonc/mdp031. Epub 2009 Mar 12. Ann Oncol. 2009. PMID: 19282468 Free article. Clinical Trial.
337 results